United States - English - NLM (National Library of Medicine)

emd serono, inc. - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 250 ug in 0.5 ml - ovidrel® prefilled syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an assisted reproductive technology (art) program such as in vitro fertilization and embryo transfer. ovidrel® prefilled syringe is also indicated for the induction of ovulation (oi) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. - before treatment with gonadotropins is instituted, a thorough gynecologic and endocrinologic evaluation must be performed. this should include an assessment of pelvic anatomy. patients with tubal obstruction should receive ovidrel® prefilled syringe only if enrolled in an in vitro fertilization program. - primary ovarian failure should be excluded by the determination of gonadotropin levels. - appropriate evaluation should be performed to exclude pregnancy. - patients in later reproductive life have a greater predisposition to endometrial carcinoma as well as a higher incidence of anovulatory disorders. a thorough diagnostic evaluation should always be performed in patients who demonstrate abnormal uterine bleeding or other signs of endometrial abnormalities before starting fsh and ovidrel® prefilled syringe therapy. - evaluation of the partner's fertility potential should be included in the initial evaluation. ovidrel® prefilled syringe (choriogonadotropin alfa injection) is contraindicated in women who exhibit: - prior hypersensitivity to hcg preparations or one of their excipients. - primary ovarian failure. - uncontrolled thyroid or adrenal dysfunction. - an uncontrolled organic intracranial lesion such as a pituitary tumor. - abnormal uterine bleeding of undetermined origin (see "selection of patients" ). - ovarian cyst or enlargement of undetermined origin (see "selection of patients" ). - sex hormone dependent tumors of the reproductive tract and accessory organs. - pregnancy.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 10000 [usp'u] in 10 ml - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity.  there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or ‘‘normal’’ distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction.  in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty.  hcg thus may help predict whether or not orchiopexy will be needed in the future.  although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary.  therapy is usually instituted between the ages four and nine. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulati

Israel - English - Ministry of Health

merck serono ltd - choriogonadotropin alfa - solution for injection - choriogonadotropin alfa 250 mcg / 0.5 ml - choriogonadotropin alfa - choriogonadotropin alfa - - for women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilization (ivf) : ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. - anovulatory or oligo-ovulatory women: ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - choriogonadotropin alfa, quantity: 250 microgram - injection, solution - excipient ingredients: mannitol; water for injections; methionine; dibasic sodium phosphate dihydrate; poloxamer; phosphoric acid; sodium hydroxide; monobasic sodium phosphate monohydrate - ovidrel is indicated in the treatment of (i) women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (ivf): ovidrel is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. (ii) anovulatory or oligo-ovulatory women: ovidrel is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 10000 [usp'u] in 10 ml - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent,

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 10000 [usp'u] in 10 ml - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovula

Canada - English - Health Canada

fresenius kabi canada ltd - chorionic gonadotropin - powder for solution - 10000unit - chorionic gonadotropin 10000unit - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - choriogonadotropin alfa - solution - 250mcg - choriogonadotropin alfa 250mcg - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - choriogonadotropin alfa - solution - 250mcg - choriogonadotropin alfa 250mcg - gonadotropins and antigonadotropins

Philippines - English - FDA (Food And Drug Administration)

zoetis philippines, inc.; distributor: zoetis philippines, inc. - gonadotropin releasing factor (gnrf) analogue protein conjugate (vet.) - solution for injection (sc) - formulation: each 2 ml (dose) contains: gonadotropin releasing factor (gnrf) analogue-protein conjugate ... (gnrf conjugated to diphtheria toxoid synthetic peptide analogue) 2300 ug.